Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
7.92B | 7.01B | 7.63B | 8.67B | 8.53B | 8.35B | Gross Profit |
3.85B | 3.37B | 4.03B | 4.60B | 4.23B | 3.69B | EBIT |
852.81M | 709.31M | 1.42B | 1.25B | 966.43M | 1.19B | EBITDA |
956.56M | 1.22B | 1.20B | 1.75B | -2.62B | 1.61B | Net Income Common Stockholders |
932.50M | 804.88M | 608.19M | 1.85B | -4.50B | 1.10B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
628.54M | 6.28B | 7.51B | 7.21B | 6.26B | 6.35B | Total Assets |
6.38B | 23.19B | 22.73B | 23.30B | 21.32B | 26.25B | Total Debt |
878.18M | 238.10M | 617.98M | 1.45B | 1.33B | 1.39B | Net Debt |
547.09M | -2.56B | -4.93B | -3.08B | -1.52B | -4.54B | Total Liabilities |
1.92B | 4.16B | 4.78B | 6.11B | 6.22B | 6.84B | Stockholders Equity |
4.38B | 19.02B | 17.96B | 17.19B | 15.09B | 19.40B |
Cash Flow | Free Cash Flow | ||||
2.10B | 954.13M | 1.25B | 879.35M | 821.95M | 565.92M | Operating Cash Flow |
2.13B | 1.13B | 1.58B | 1.12B | 1.11B | 782.50M | Investing Cash Flow |
-2.48B | -3.39B | 528.10M | 936.23M | -4.19B | -1.29B | Financing Cash Flow |
-107.68M | -510.82M | -1.15B | -349.99M | -92.34M | -1.93B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $4.72T | 22.22 | 21.25% | 0.64% | 8.88% | 54.27% | |
78 Outperform | HK$228.41B | 13.46 | 27.71% | ― | 9.84% | 142.09% | |
78 Outperform | €253.24B | 75.82 | 33.41% | 0.17% | 103.44% | 186.51% | |
76 Outperform | $1.31T | 48.83 | 13.43% | ― | 32.62% | 32.85% | |
70 Outperform | $851.70B | 21.27 | 22.27% | ― | 19.90% | 157.52% | |
63 Neutral | HK$27.06B | 27.55 | -1.14% | ― | 13.74% | -125.64% | |
60 Neutral | $14.02B | 6.62 | -2.88% | 3.71% | 2.35% | -37.08% |
China Literature Limited has announced its upcoming annual general meeting scheduled for May 30, 2025, in Hong Kong. Key agenda items include the consideration of audited financial statements, re-election of directors, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares and related securities, reflecting the company’s strategic focus on expanding its financial and operational capabilities. This announcement underscores the company’s commitment to maintaining robust corporate governance and enhancing shareholder value.
China Literature Limited reported its annual results for 2024, showing a 15.8% increase in revenues to RMB 8.1 billion, despite an operating loss of RMB 336 million. The company highlighted the success of its IP operations, with revenues rising 34% year-over-year, driven by blockbuster titles and the commercialization of popular content like ‘Ne Zha 22.’ The integration of AI technologies, such as the DeepSeek-R1 model in their ‘Writer Assistant’ tool, has enhanced content creation, leading to significant growth in user engagement and new writer income. These developments underscore China Literature’s strategic focus on quality content and technological innovation, reinforcing its leading position in the industry.
China Literature Limited has issued a profit warning, anticipating a net loss of RMB150 million to RMB250 million for the 2024 financial year, primarily due to a non-cash impairment of goodwill from its 2018 acquisition of New Classics Media Holdings Limited. Despite the expected loss, the company plans to focus on developing top-tier film and drama content, which may lead to higher production costs and extended project timelines. However, this strategic shift is expected to strengthen its market position and create long-term value for its intellectual property business.